The ASX dodged a heavier fall in early trading on Wednesday, with money leaking out of tech and crypto and drifting back ...

While Alzheimer's drug developers have spent billions on suboptimal treatments, Actinogen strives for a breakthrough with a ...

As the gold price goes gangbusters, these near-term producers are aiming to get mines up and running this year.

Stockhead’s Tylah Tully previews the 2026 ahead for Maronan Metals (ASX:MMA) and recaps the goals the company achieved ...

Crypto adoption is accelerating globally, but Kraken says Australia needs to see legislation passed to enable better adoption ...

Australian tech was the ASX’s weakest sector in January as rate hikes bit, but brokers say the 2026 outlook remains constructive.

Everest Metals (ASX:EMC) has delivered a string of broad and high-grade rubidium intercepts at its Mt Edon critical minerals ...

Broad, high-grade copper-gold results from Solstice Minerals at Nanadie include the best-ever grade intercept to date.

Neuren Pharmaceutical shares are tumbling after Europe's drug gatekeeper indicated it would not approve the company's Rett syndrome therapy.

The ASX 200 recovered most of yesterday’s losses in a broad-based rally, resisting interest-rate-hike headwinds.

The ASX surged by lunch in the eastern states, with tech and miners leading a bounce … while the RBA decision was looming.

Tasmanian miners spent a record $13 million exploring in September 2025 as the Apple Isle emerges as a hidden gem of the ...